The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib for the treatment of patients ...
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026LONDON and PHILADELPHIA, (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback